Three things to know:
1. Carmell Therapeutics develops plasma-based bioactive materials to accelerate bone and soft tissue healing.
2. In a Phase II clinical trial for open tibia fractures, the company’s bone healing accelerant showed a significant reduction of infections compared to controls, with a clear path toward accelerated wound healing at 30 days.
3. The product can be administered in several forms, including putties, pastes and surgical screws.
More articles on biologics:
AAOS publishes clinical considerations for return to elective surgery
97% of medical practices suffer COVID-19 financial hit: 5 observations for orthopedics
Investor pays $49M for Arizona spine, orthopedic hospital property
